OC
BBIO icon

Oppenheimer & Co’s BridgeBio Pharma BBIO Stock Holding History

Oppenheimer & Co’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$515K Hold
6,939
– – 0.01% 1178
2025
Q4 		$531K Sell
6,939
-906
-12% -$59.5K 0.01% 1059
2025
Q3 		$407K Buy
+7,845
New +$383K 0.01% 1259

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oppenheimer & Co's BBIO Position: Q1 2026 in Review

Oppenheimer & Co held its BridgeBio Pharma (BBIO) position steady in Q1 2026 at 6,939 shares worth $515K. The position accounts for 0.01% of the portfolio, ranked #1178.

Oppenheimer & Co first reported a position in BBIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $531K in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Oppenheimer & Co held 6,939 shares of BridgeBio Pharma worth $515K as of Q1 2026.
  • Oppenheimer & Co left its BridgeBio Pharma share count unchanged in Q1 2026.
  • BridgeBio Pharma made up 0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #1178 holding.
  • Oppenheimer & Co first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 3 quarters since.
  • Oppenheimer & Co's BridgeBio Pharma position peaked at $531K in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.